Platelet storage solution improves the in vitro function of preserved platelet concentrate

The Role of Glutamine in the Prevention of Ultraviolet-C-Induced Platelet Activation

Background and Objectives. The primary function of platelets is to prevent bleeding. The use of UV-C light in the treatment of platelets has become a valuable method for preserving the efficacy of platelet concentrates in blood banks. However, its deleterious effect remains, such as the activation of platelets, thus causing the platelets to lose their physiological function. In this study, we intended to demonstrate the impact of UV-C on platelets and how the use of glutamine could mitigate the loss of physiological function of the platelets caused by UV-C. Materials and Methods. This study was conducted using mouse platelets. We assessed calcium signaling using Fura-2 AM incubation and dense granule secretion of the platelets using luminescence assay by measuring ATP. At the molecular level, the activation of integrin using PAC-1 antibody was analyzed. Phosphorylation of immune-precipitated cPLA2 was assessed using a specific antibody. All the experiments were carried out with or without glutamine in the presence of UV-C. Positive and negative controls were used in all experiments to validate the findings. Results. We have demonstrated that physiological and biochemical damage arises as a result of the exposure of platelet concentrate to UV-C and that the use of glutamine could alleviate this damage. Various experiments, thrombus formation, integrin activation, and phosphorylation of cPLA2 were preserved using 50 mM of glutamine in the presence of UV-C, which reduces 50% of platelet viability. Conclusions. Our study demonstrates that the storage of platelet concentrates under the UV-C activates their physiological process and renders them to the thrombus formation, hence decreasing their viability. The presence of a moderate amount of glutamine can alleviate the toxic effect of UV-C, and platelet concentrates could be kept viable for a long time.

A novel assay for the detection of anti-human platelet antigen antibodies (HPA-1a) based on peptide aptamer technology

BACKGROUND

Neonatal alloimmune thrombocytopenia is mostly due to the presence of maternal antibodies against the fetal platelet antigen HPA-1a on the platelet integrin GPIIb-IIIa. Accurate detection of anti-HPA-1a antibodies in the mother is, therefore, critical. Current diagnostic assays rely on the availability of pools of human platelets that vary according to donors and blood centers. There is still no satisfactory standardization of these assays.

DESIGN AND METHODS

Peptide aptamer was used to detect and identify HPA-1a-specific antibodies in human serum that do not require human platelets. A peptide aptamer library was screened using an anti-HPA-1a human monoclonal antibody as a bait to isolate an aptamer that mimics the human platelet antigen HPA-1a.

RESULTS

This is the first report in platelet immunology of the use of a peptide aptamer for diagnostic purposes. This assay gives better results than the MAIPA currently in use, detecting around 90% of the expected alloantibodies.

CONCLUSIONS

This assay could help define a standard for the quantitation of anti-HPA antibodies. This report also demonstrates that peptide aptamers can potentially detect a variety of biomarkers in body fluids; this is of particular interest for diagnostic purposes.

Dermal benefits of topical D-ribose

Our aging skin undergoes changes with reductions in collagenous and elastic fibers, fibroblasts, mast cells, and macrophages with free radical production, which can result in reduced skin tone and wrinkle formation. Fibroblasts are important for dermal integrity and function with a decrease in function producing less skin tone, thinning, and wrinkle formation. Dermal levels of adenosine triphosphate (ATP) decline with aging, potentially altering dermal function. Supplemental D-ribose, a natural occurring carbohydrate, enhances ATP regeneration. D-ribose-based studies demonstrated benefits in both cell culture fibroblastic activities and a subsequent clinical study in women with decreased skin tone with wrinkles. Supplemental D-ribose may offer this needed cellular benefit.

Preservation of Platelets by Adding Epigallocatechin-3-O-Gallate to Platelet Concentrates

The effect of epigallocatechin-3- O-gallate (EGCG), a major component of green tea, on platelet preservation was evaluated. Single donor platelets ( N = 10) were collected and preserved by the standard method. EGCG was added to the platelet concentrates before preservation and then the functional and biochemical parameters were monitored throughout the storage period. After 6 days of preservation, the aggregability of the platelets was significantly maintained by addition of 50 and 100 μg/ml of EGCG. Platelet prothrombinase activity was also significantly retained by the addition of EGCG. The accumulation of P-selectin and RANTES in the plasma preserved with EGCG was less than those preserved without EGCG, which indicated that EGCG might inhibit platelet activation. Furthermore, EGCG reduced the increase of LDH in plasma during preservation and inhibited the activation of caspase-3 and cleavage of gelsolin, thereby showing that EGCG could inhibit the apoptosis of platelets. These results suggest that EGCG may play an effective role in preserving platelets by inhibiting the activation and apoptosis of platelets.

Buffy-coat platelet variables and metabolism during storage in additive solutions or plasma

BACKGROUND

Buffy-coat processing allows for the use of platelet additive solutions (PASs). PASs reduce plasma-associated transfusion reactions and conserve plasma for transfusion or fractionation. Platelet (PLT) storage in plasma was compared to storage in three commercially available PASs compared to assess their influence on in vitro laboratory variables.

STUDY DESIGN AND METHODS

Platelet concentrates (PCs) were prepared from leukoreduced pools of four buffy coats (BCPs) suspended in autologous plasma or one of PASs (Composol, Fresenius-Kabi; T-Sol, Baxter Corp.; or SSP+, MacoPharma). On Days 1, 2, 3, 5, and 7 of storage, samples were tested for PLT concentration, mean PLT volume (MPV), CD62P, morphology, pO2, pCO2, glucose, lactate and total protein concentration, pH, extent of shape change (ESC), and hypotonic shock response (HSR). Data were analyzed by analysis of variance (ANOVA) with repeated measures and t tests.

RESULTS

PLT recoveries from BCPs were higher (p < 0.05) with plasma than any PAS. Storage medium and duration did not affect PLT concentration or MPV over time. CD62P expression and morphology were significantly different among PCs pooled with different media. ANOVA showed (p < 0.05) differences among the rates of change of pCO2, pH, glucose consumption, lactate production, and ESC; PASs such as Composol and SSP+ offered excellent maintenance of pH and low rates of glucose consumption. PAS performed poorly in ESC and HSR compared to plasma. Correlation studies reveal far more significant correlations between variables of PLTs in PAS than in plasma.

CONCLUSION

Newer PASs, for example, SSP+ and Composol, can maintain PLT integrity and moderate metabolism similarly to plasma but offer consistently lower PLT recoveries and limited osmotic balance.

[Platelet-washing solution optimization]

Different washing and homogénéisation solutions are hereby analysed by comparing the evolution of functional indicators during the preservation of washed aphaeresis platelet concentrates: physiological pH 4.5 and 6 solutions, buffered physiological pH 6.8 glucose solution, and two physiological pH 7 citrate solutions with acetate. Prior acidification of platelet concentrates proved to be essential. Two washings with manual or automated technique, guarantee residual proteins at a level of less than 0.5 g. Solutions T-Sol Baxter or SSP Macopharma allow us to obtain a product that meet the PSL specifications. Routine since June 2004, washings are done with a physiological pH 6 solution, then homogeneised with T-Sol solution. Platelet recovery, swirling phenomenon, lack of agrgegates, pH maintenance, low increase in the platelet average volume and maintenance of intra-cell potassium level, suggest that platelet entirety is preserved beyond the product's expiration date. The platelet transfusion yield of these products is satisfactory.